First IRB approval for APTN-101’s Ph 1 trial in GBM granted, enabling patient recruitment to begin
“Following the successful preclinical development and acceptance of our Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA), we are extremely pleased to receive our first IRB approval for APTN-101’s Phase I clinical trial,” said Michael J. Roberts, Ph.D., Chief Executive Officer of Adaptin Bio. “This represents a major inflection point for our lead program and validates the translation readiness of our targeted bispecific antibody platform. In collaboration with Duke University investigators, the inventors of our BRiTE platform, APTN-101 demonstrated compelling anti-tumor activity and a favorable safety profile in multiple preclinical models. With clinical, manufacturing, and regulatory foundations now in place, we are positioned to advance APTN-101 into the clinic and work toward delivering a meaningful new therapeutic option for patients facing a devastating disease.”
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo